Castle Biosciences Inc (CSTL)

Sep 26, 2026

Wall Street Zen has upgraded Castle Biosciences (NASDAQ:CSTL) from a "hold" to a "buy" rating. This upgrade follows the company's strong quarterly performance, where it exceeded revenue expectations with $99.86 million and reported a lower-than-expected adjusted loss of $0.07 per share. Despite significant insider selling, institutional ownership remains high, indicating confidence from major investors.

Sep 24, 2026

Castle Biosciences insider Derek Maetzold sold 8,580 shares of the company's stock for approximately $303,131, reducing his direct stake by 28.54%. The transaction was made under a pre-arranged Rule 10b5-1 plan. Despite the insider sale, analysts maintain a "Moderate Buy" rating for Castle Biosciences, with the stock trading near its 52-week high after exceeding revenue and earnings expectations in its latest quarter.

Sep 17, 2026

Castle Biosciences' Chief Commercial Officer, Juvenal Tobin W, sold a total of 6,600 shares in two open-market transactions on September 14 and 15, 2026, at prices ranging from $32.32 to $35.14 per share. Following these sales, Tobin W now holds 58,584 shares, representing approximately 10.1% of his previous holdings. This provides investors with insight into his updated ownership stake in the company.

Sep 17, 2026

Castle Biosciences insider Tobin Juvenal sold 3,294 shares of the company's stock for approximately $115,751 on September 15th, reducing his position by 5.32%. Despite this insider sale, the company recently reported strong quarterly revenue and an adjusted loss per share that exceeded analyst expectations. Analysts generally maintain a "Moderate Buy" rating for CSTL with an average price target of $42.

Sep 16, 2026

Tobin Juvenal, an insider at Castle Biosciences (NASDAQ:CSTL), sold 3,306 shares of the company's stock on September 14th, 2026, for approximately $106,850. This transaction reduced his total holdings by 5.07% to 61,878 shares. Despite the insider sale, analysts have a "Moderate Buy" consensus rating for CSTL with an average price target of $42.00, following the company's Q2 earnings which surpassed revenue and EPS estimates.

Sep 15, 2026

A new decision modeling study by Castle Biosciences (NASDAQ: CSTL) indicates that its TissueCypher test can significantly improve risk-aligned management decisions for patients with Barrett's esophagus. The study found that incorporating TissueCypher results increased appropriate treatment decisions from 59.8% to 75.3%, notably reducing both undertreatment in progressing patients and overtreatment in non-progressing patients. While the study highlights the test's potential clinical utility, it was based on modeling rather than actual patient outcomes, suggesting a need for future real-world studies.